and biologic therapies that aim to disrupt key pathways driving tumor growth and survival. The company’s research approach combines target discovery, medicinal chemistry, and preclinical validation to progress programs toward clinical evaluation with the goal of addressing unmet needs in oncology. Diagonal Therapeutics also collaborates with academic partners and leverages external datasets to inform its therapeutic strategies and enhance predictive models for treatment response. Its pipeline includes programs across multiple cancer types that are designed to exploit specific genetic or phenotypic vulnerabilities in tumor cells.